Effect of anti-CD20 monoclonal antibody (rituximab) on recalcitrant pemphigus vulgaris

Mi Ri Kim, SooChan Kim

Research output: Contribution to journalArticle

Abstract

Background: Pemphigus is a severe blistering disorder caused by autoantibodies to desmogleins 1 and 3. Because some patients with pemphigus never enter into remission, new immunosuppressants are warranted. Rituximab is a chimeric monoclonal antibody binding to the CD20 antigen on B cells, which proved to be effective in recalcitrant pemphigus. Objective: The purpose of this study was to evaluate the efficacy and safety of Rituximab in the treatment of refractory pemphigus vulgaris. Methods: A retrospective analysis was conducted of six patients with recalcitrant pemphigus vulgaris in Yongdong Severance Hospital. Rituximab was administered intravenously at a dosage of 375 mg/m body surface area. Five patient received 2 cycles of Rituximab treatment with an interval of 7 days. One patient received 5 cycles of treatment. The mean follow-up after treatment was 9.3 months (range, 2 months to 16 months). Results: All the patients presented clinical improvements. The average pemphigus vulgaris severity score decreased from 12.2 to 2.5 after treatment. No adverse effects were observed. Conclusion: Rituximab has been proved as an effective and safe treatment for refractory pemphigus vulgaris.

Original languageEnglish
Pages (from-to)319-324
Number of pages6
JournalKorean Journal of Dermatology
Volume46
Issue number3
Publication statusPublished - 2008 Jul 11

Fingerprint

Pemphigus
Monoclonal Antibodies
Therapeutics
Desmoglein 3
CD20 Antigens
Desmoglein 1
Body Surface Area
Immunosuppressive Agents
Rituximab
Autoantibodies
B-Lymphocytes
Safety

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

@article{0bc5f7febf4c483fb333ff964cff76a1,
title = "Effect of anti-CD20 monoclonal antibody (rituximab) on recalcitrant pemphigus vulgaris",
abstract = "Background: Pemphigus is a severe blistering disorder caused by autoantibodies to desmogleins 1 and 3. Because some patients with pemphigus never enter into remission, new immunosuppressants are warranted. Rituximab is a chimeric monoclonal antibody binding to the CD20 antigen on B cells, which proved to be effective in recalcitrant pemphigus. Objective: The purpose of this study was to evaluate the efficacy and safety of Rituximab in the treatment of refractory pemphigus vulgaris. Methods: A retrospective analysis was conducted of six patients with recalcitrant pemphigus vulgaris in Yongdong Severance Hospital. Rituximab was administered intravenously at a dosage of 375 mg/m body surface area. Five patient received 2 cycles of Rituximab treatment with an interval of 7 days. One patient received 5 cycles of treatment. The mean follow-up after treatment was 9.3 months (range, 2 months to 16 months). Results: All the patients presented clinical improvements. The average pemphigus vulgaris severity score decreased from 12.2 to 2.5 after treatment. No adverse effects were observed. Conclusion: Rituximab has been proved as an effective and safe treatment for refractory pemphigus vulgaris.",
author = "Kim, {Mi Ri} and SooChan Kim",
year = "2008",
month = "7",
day = "11",
language = "English",
volume = "46",
pages = "319--324",
journal = "Korean Journal of Dermatology",
issn = "0494-4739",
publisher = "Korean Dermatological Association",
number = "3",

}

Effect of anti-CD20 monoclonal antibody (rituximab) on recalcitrant pemphigus vulgaris. / Kim, Mi Ri; Kim, SooChan.

In: Korean Journal of Dermatology, Vol. 46, No. 3, 11.07.2008, p. 319-324.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of anti-CD20 monoclonal antibody (rituximab) on recalcitrant pemphigus vulgaris

AU - Kim, Mi Ri

AU - Kim, SooChan

PY - 2008/7/11

Y1 - 2008/7/11

N2 - Background: Pemphigus is a severe blistering disorder caused by autoantibodies to desmogleins 1 and 3. Because some patients with pemphigus never enter into remission, new immunosuppressants are warranted. Rituximab is a chimeric monoclonal antibody binding to the CD20 antigen on B cells, which proved to be effective in recalcitrant pemphigus. Objective: The purpose of this study was to evaluate the efficacy and safety of Rituximab in the treatment of refractory pemphigus vulgaris. Methods: A retrospective analysis was conducted of six patients with recalcitrant pemphigus vulgaris in Yongdong Severance Hospital. Rituximab was administered intravenously at a dosage of 375 mg/m body surface area. Five patient received 2 cycles of Rituximab treatment with an interval of 7 days. One patient received 5 cycles of treatment. The mean follow-up after treatment was 9.3 months (range, 2 months to 16 months). Results: All the patients presented clinical improvements. The average pemphigus vulgaris severity score decreased from 12.2 to 2.5 after treatment. No adverse effects were observed. Conclusion: Rituximab has been proved as an effective and safe treatment for refractory pemphigus vulgaris.

AB - Background: Pemphigus is a severe blistering disorder caused by autoantibodies to desmogleins 1 and 3. Because some patients with pemphigus never enter into remission, new immunosuppressants are warranted. Rituximab is a chimeric monoclonal antibody binding to the CD20 antigen on B cells, which proved to be effective in recalcitrant pemphigus. Objective: The purpose of this study was to evaluate the efficacy and safety of Rituximab in the treatment of refractory pemphigus vulgaris. Methods: A retrospective analysis was conducted of six patients with recalcitrant pemphigus vulgaris in Yongdong Severance Hospital. Rituximab was administered intravenously at a dosage of 375 mg/m body surface area. Five patient received 2 cycles of Rituximab treatment with an interval of 7 days. One patient received 5 cycles of treatment. The mean follow-up after treatment was 9.3 months (range, 2 months to 16 months). Results: All the patients presented clinical improvements. The average pemphigus vulgaris severity score decreased from 12.2 to 2.5 after treatment. No adverse effects were observed. Conclusion: Rituximab has been proved as an effective and safe treatment for refractory pemphigus vulgaris.

UR - http://www.scopus.com/inward/record.url?scp=46649093969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46649093969&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:46649093969

VL - 46

SP - 319

EP - 324

JO - Korean Journal of Dermatology

JF - Korean Journal of Dermatology

SN - 0494-4739

IS - 3

ER -